

Supplementary Online Content

Shoulders A, Andrews CM, Westlake MA, Abraham AJ, Grogan CM. Changes in Medicaid fee-for-service benefit design for substance use disorder treatment during the opioid crisis, 2014 to 2021. *JAMA Health Forum*. 2023;4(8):e232502. doi:10.1001/jamahealthforum.2023.2502

eTable 1. Percentage Data Corresponding to Figures 1 to 4

eTable 2. Count Data Corresponding to Figures 1 to 4

eTable 3. Nonrespondent US States for Each Survey Wave

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Percentage Data Corresponding to Figures 1 to 4

	Coverage			Copayments			Prior Authorization			Annual Maximums		
	2014	2017	2021	2014	2017	2021	2014	2017	2021	2014	2017	2021
Individual outpatient	94%	96%	100%	23%	27%	24%	42%	34%	22%	49%	23%	26%
Group outpatient	96%	98%	100%	23%	27%	24%	41%	33%	22%	48%	22%	26%
Intensive outpatient	82%	84%	90%	24%	27%	18%	45%	40%	29%	50%	18%	10%
Short-term residential	61%	71%	87%	11%	13%	13%	74%	58%	53%	41%	26%	17%
Long-term residential	43%	51%	67%	17%	18%	8%	63%	52%	68%	22%	18%	14%
Recovery support	47%	51%	87%	14%	14%	18%	65%	46%	27%	44%	20%	17%
Detoxification (any)	90%	90%	95%	17%	20%	23%	61%	57%	45%	29%	10%	15%
Detoxification (outpatient)			67%			10%			24%			14%
Detoxification (inpatient)			93%			23%			49%			16%
Methadone maintenance	65%	78%	92%	23%	31%	19%	48%	40%	14%	27%	14%	3%
Oral naltrexone	73%	88%	100%	51%	53%	33%	43%	26%	10%	12%	14%	0%
Injectable naltrexone	94%	94%	100%	43%	45%	32%	72%	51%	21%	23%	11%	3%
Buprenorphine	100%	100%	100%	47%	51%	32%	84%	69%	33%	31%	25%	3%

eTable 2. Count Data Corresponding to Figures 1 to 4

	Coverage			Copayments			Prior Authorization			Annual Maximums		
	2014	2017	2021	2014	2017	2021	2014	2017	2021	2014	2017	2021
Individual outpatient	48	49	40	10	12	9	18	15	8	21	10	9
Group outpatient	49	50	40	10	12	9	18	15	8	21	10	9
Intensive outpatient	42	43	36	9	10	6	17	15	10	19	7	3
Short-term residential	31	36	34	3	4	4	20	18	17	11	8	5
Long-term residential	22	26	26	3	4	2	12	12	17	4	4	3
Recovery support	24	26	34	3	3	6	13	10	9	8	4	5
Detoxification (any)	46	46	38	7	8	9	25	23	18	12	4	6
Detoxification (outpatient)			30			3			7			4
Detoxification (inpatient)			37			8			17			5
Methadone maintenance	33	40	36	7	11	7	15	15	5	8	5	1
Oral naltrexone	37	45	40	19	25	13	16	12	4	4	6	0
Injectable naltrexone	48	48	40	20	22	12	33	25	8	10	5	1
Buprenorphine	51	51	40	24	26	12	42	35	13	15	12	1

eTable 3. Nonrespondent US States for Each Survey Wave

	Non-Respondent States
2014	Kentucky, Maryland, Nebraska, New York
2017	Minnesota, Nebraska, New Hampshire, Utah
2021	Iowa, South Dakota, Wisconsin, Arkansas, and Delaware